Parkinson's Disease Quality of Life (PDQUALIF) - away from social scale
General Details:
Name:
Parkinson's Disease Quality of Life (PDQUALIF) - away from social scale
Steward:
NINDS
Definition:
Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Registration Status:
Qualified
Permissible Values:
Data Type:
Value List
Unit of Measure:
Ids:
Value
Code Name
Code
Code System
Code Description
Strongly Agree
Strongly Agree
Strongly Agree
Somewhat Agree
Somewhat Agree
Somewhat Agree
Agree
Agree
Agree
Somewhat disagree
Somewhat disagree
Somewhat disagree
Strongly Disagree
Strongly Disagree
Strongly Disagree
Designations:
Designation:
Parkinson's Disease Quality of Life (PDQUALIF) - away from social scale
Tags:
Designations:
Definition:
Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Tags:
Reference Documents:
ID:
Title:
URI:
Provider Org:
Language Code:
Document:
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.